Concert Pharmaceuticals Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
64
- Latest Deal Type
-
M&A
- Financing Rounds
-
15
Concert Pharmaceuticals General Information
Description
Manufacturer of biopharmaceutical drugs intended for the treatment of alopecia areata. The company offers orally administered small molecules or repurpose-approved drugs, enabling patients with cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder and Alzheimer's agitation to access innovative treatments.
Contact Information
Website
www.concertpharma.comCorporate Office
- 65 Hayden Avenue
- Suite 3000N
- Lexington, MA 02421
- United States
Corporate Office
- 65 Hayden Avenue
- Suite 3000N
- Lexington, MA 02421
- United States
Concert Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Concert Pharmaceuticals Comparisons
Industry
Financing
Details
Concert Pharmaceuticals Competitors (44)
One of Concert Pharmaceuticals’s 44 competitors is Quince Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quince Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Neuphoria Therapeutics | Formerly VC-backed | Burlington, MA |
Concert Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Concert Pharmaceuticals Patents
Concert Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2018188474-A | Deuterated cftr potentiator | Active | 13-Aug-2018 | ||
| JP-2018172421-A | Deuteration derivatives of ruxolitinib | Active | 05-Jul-2018 | ||
| AU-2019239096-A1 | Deuterated analogs of d-beta-hydroxybutyric acid and uses thereof | Inactive | 23-Mar-2018 | ||
| EP-3768253-A1 | Deuterated analogs of d-& x3b2;-hydroxybutyric acid and uses thereof | Inactive | 23-Mar-2018 | ||
| US-20210008018-A1 | Deuterated analogs of d-beta-hydroxybutyric acid and uses thereof | Inactive | 23-Mar-2018 | A61K31/19 |
Concert Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Concert Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Concert Pharmaceuticals FAQs
-
When was Concert Pharmaceuticals founded?
Concert Pharmaceuticals was founded in 2006.
-
Where is Concert Pharmaceuticals headquartered?
Concert Pharmaceuticals is headquartered in Lexington, MA.
-
What is the size of Concert Pharmaceuticals?
Concert Pharmaceuticals has 64 total employees.
-
What industry is Concert Pharmaceuticals in?
Concert Pharmaceuticals’s primary industry is Biotechnology.
-
Is Concert Pharmaceuticals a private or public company?
Concert Pharmaceuticals is a Private company.
-
What is the current valuation of Concert Pharmaceuticals?
The current valuation of Concert Pharmaceuticals is .
-
What is Concert Pharmaceuticals’s current revenue?
The current revenue for Concert Pharmaceuticals is .
-
How much funding has Concert Pharmaceuticals raised over time?
Concert Pharmaceuticals has raised $333M.
-
Who are Concert Pharmaceuticals’s investors?
Adage Capital Management, Brookside Capital, Fidelity Investments, Flagship Pioneering, and Foresite Capital are 5 of 16 investors who have invested in Concert Pharmaceuticals.
-
Who are Concert Pharmaceuticals’s competitors?
Quince Therapeutics, Neurogene, CRISPR Therapeutics, Vertex Pharmaceuticals, and Neuphoria Therapeutics are some of the 44 competitors of Concert Pharmaceuticals.
-
When was Concert Pharmaceuticals acquired?
Concert Pharmaceuticals was acquired on 06-Mar-2023.
-
Who acquired Concert Pharmaceuticals?
Concert Pharmaceuticals was acquired by Sun Pharmaceutical Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
